 |
56 Diseases |  |
40 Trials |
|
40 Trials |  |
3062 News |  |
| «12...89101112131415161718...3738» |
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Blincyto (blinatumomab) / Astellas, Amgen
Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_5854;
High rates of deep molecular response were observed in R/R Ph+ ALL. However, CMR rates were relatively low in pts with CML-LBP, suggesting that alternative approaches should be considered in these pts.
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Dasatinib and Ponatinib in Lck-Activated T-Cell Acute Lymphoblastic Leukemia (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_5789;
Although it is unclear whether this mutation would occur in T-ALL patients undergoing dasatinib treatment, our findings point to the need for evaluating multiple LCK inhibitors as a treatment option. In conclusion, we comprehensively characterized pharmacokinetic and pharmacodynamic profile of dasatinib and ponatinib in preclinical models of T-ALL, and our exposure-response modeling established human dosage levels for future trials of LCK inhibitor for this cancer.
- Scemblix (asciminib) / Novartis
Clinical Outcomes of Chronic Myeloid Leukaemia (CML) Patients on Asciminib through the Managed Access Program (MAP) in Australia (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_4411;
In this heavily pre-treated population of CML patients most of whom had underlying medical comorbidities, asciminib was generally well-tolerated and demonstrated excellent responses more so in favour of the TKI-intolerant patients, which are associated with improved long-term outcomes. These results validate the role of asciminib as a useful novel CML treatment.
- Scemblix (asciminib) / Novartis
Real-World Experience of Asciminib: Factors Associated with Response (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_4409;
While the presence of T315I mutations does not appear to significantly impact on the response to asciminib, the presence of non-T315I mutations is associated with a lower rate of MMR. Importantly the standard dosing regimen in patients with T315I mutations is fivefold higher but whether this explains the discrepant responses to T315I and non-T315I mutations requires further investigation.
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Last Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib ||Topase|| in Patients with TKI-Resistant or Intolerant CML (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_4400;
In a population of pts highly representative of TKI-resistant French CML pts, we report here a response improvement for 60% of CP-CML pts (MMR achievement) and 66.7% of AP/BP pts (CHR achievement). Ponatinib treatment dose was rapidly adapted (within 3 months) whatever the initial treatment dose limiting the number and severity of the AEs.
- Scemblix (asciminib) / Novartis
Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_4395;
P2
In a phase III trial, asciminib was more active than bosutinib in a phase III trial in patients who had received 2 prior TKIs Our primary objective in this study is to determine the 1-year TFR rate after 12 months of combination therapy with imatinib plus asciminib, followed by treatment cessation, in subjects who have previously had molecular recurrence first TFR attempt...This design yields a type I error rate of 5% and power of 85% when the true TFR rate is 65%. To account for a potential dropout rate of 8% due to adverse events or loss of response, 51 patients will be enrolled to achieve the 47 patients needed.
- Bosulif (bosutinib) / Pfizer, Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Tasigna (nilotinib) / Novartis, Inhibikase
Trends in Frontline Treatment and Overall Survival in the Era of Targeted Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_4394;
Though survival has improved for all pts, pts from traditionally underserved populations, including those who are underinsured or from low-income or low-education areas, have reduced survival. Continued advances in treatment and efforts to improve access to care for underserved populations is vital in the goal to achieve equitable survival outcomes in CML.
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Molecular Response of =10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_4393;
In this landmark analysis, attainment of =10% BCR::ABL1IS with ponatinib within 12 months was associated with improved long-term PFS outcomes compared with PFS outcomes associated with remaining at >10% BCR::ABL1IS. These findings underpin the clinical benefit of achieving molecular responses with ponatinib, especially achieving =10% BCR::ABL IS within 12 months.
- Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after =2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_4392;
Pts on asciminib achieved MMR regardless of the last TKI and reason for discontinuation (resistance/intolerance), and overall MMR rates at wk 96 were higher with asciminib than BOS across all last prior TKIs. In pts with resistance to all prior lines of 2G TKIs, MMR rates at wk 96 were higher with asciminib than BOS and comparable to the previously published MMR rate of all pts randomized to receive asciminib (37.6 %).
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Thrombogenesis Mechanisms of High Doses of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) Compared to Tyrosine Kinase Inhibitors (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_4379;
Our results also suggest that the vaso-occlusive events of ponatinib are mainly due to endothelial damage rather than platelet dysfunction, with a critical role for thromboinflammatory markers such as VWF, NETs and TF. Indeed, plasma TF levels were remarkably elevated in ponatinib-treated patients vs.
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Blincyto (blinatumomab) / Astellas, Amgen
A Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_4158;
Pts received mini-hyper-CVD alternating with methotrexate and cytarabine on cycles 1-4, followed by blinatumomab and ponatinib on cycles 5-8...Pts with CD20+ disease received rituximab on cycles 1-4...Following consolidation, pts received maintenance therapy with 15 cycles of ponatinib plus vincristine/prednisone (maintenance cycles 1-3, 5-7, 9-11, and 13-15) alternating with ponatinib plus blinatumomab (maintenance cycles 4, 8, and 12) followed by ponatinib monotherapy daily for at least 5 years...One pt discontinued ponatinib and switched to dasatinib due to pulmonary embolism that occurred in cycle 2...The 30- and 60-day mortality rates were 0%. Conclusion Sequential combination of low-intensity chemotherapy and ponatinib followed by blinatumomab and ponatinib is highly effective and well tolerated in Ph+ ALL.
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry (ENMCC - 388-390) - Nov 4, 2022 - Abstract #ASH2022ASH_3657;
Twenty (31%) pts received imatinib (IM) at late pregnancy: Me start was 18 w (range 16-34)...Seven (11%) pts received hydroxycarbamide (HC) as monotherapy or in combination with IFN or IM...However, 3 pts unfortunately died 19, 24 and 119 mo after pregnancy completion, the reasons were not thought to be related to management in pregnancy: non-compliance, progression/resistance (1 case with T315/F359 mutation in the time of pre-ponatinib availability) and death after bone marrow transplantation...IM is probably safe in 2nd- 3rd trim considering its limited placental crossing. The use of HC is more questionable, as it has no advantages over IM and passes freely to the placenta: its use may be acceptable if there is a need for the urgent cytoreduction and leucapheresis is not available.
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (ENMCC - 388-390) - Nov 4, 2022 - Abstract #ASH2022ASH_3656;
P2
Results from the 3-year follow-up of the Phase 2 OPTIC study provide the robust long-term efficacy and manageable safety profile of ponatinib in a highly resistant CP-CML population. Consistent with results from the primary analysis, a ponatinib starting dose of 45 mg/d with reduction to 15 mg/d upon attainment of =1% BCR::ABL1IS provided the optimal benefit:risk ratio.
- Global Representation in Phase 2 and Phase 3 Clinical Trials for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_3196;
In addition, findings show that lower SDI countries had fewer approvals for TKIs leading to further disparities. This reveals a disparity that is important to address.
- vincristine / Generic mfg.
Patterns of Neuropathy in ALL Patients Treated with Vincristine Based Regimens with and without Tyrosine Kinase Inhibitors (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_3154;
However, the majority of our patients received dasatinib rather than nilotinib, which has been the focus of recent pre-clinical studies. Our findings may suggest a potential mechanistic difference in the effects of dasatanib and nilotinib on the neuronal transport of VCR.
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Tasigna (nilotinib) / Novartis, Inhibikase
Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2978;
Toxicity leading to TKI interruptions, discontinuation, and dose reduction was common. Post-transplant outcomes were comparable with imatinib and NG-TKI.
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Consolidation with Allogeneic Hematopoietic Cell Transplant Improved Survival Outcomes of Adults with Relapsed / Refractory Acute Lymphoblastic Leukemia Following Response to Memory-Enriched CD19CAR T Cells (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2886;
P1
The median number of prior lines of therapy was 3 (range, 1-9); 29 (63%) pts had prior alloHCT, and 29 (63%) and 15 (33%) pts failed blinatumomab and inotuzumab before enrollment, respectively...Of the 19 pts who responded to CAR T cells and did not have alloHCT consolidation, 11 relapsed with a median time of 3.4 months (range, 2.1-10.3) post CAR T cell infusion, 3 pts died in remission, and 5 pts remained alive and in remission at last contact or date of censoring, with a median follow up of 9.7 months (range, 3.3-51.8) including 1 pt who was censored at day 99 post infusion upon initiating ponatinib maintenance... Outcomes of alloHCT consolidation in adults with high-risk r/r ALL after achieving remission with Tn/mem CD19CAR T cells were promising, including for pts receiving their second alloHCT, and transplant led to improved survival outcomes.
- Scemblix (asciminib) / Novartis
Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2566;
Asciminib is a molecule with a good safety profile, with a lower rate of AEs compared to classical TKIs. However, this drug, despite its novel mechanism of action presents risk of cross-intolerance with classical TKIs for some toxicities, including hematologic toxicity, fatigue, vomiting and pancreatitis.
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Tasigna (nilotinib) / Novartis, Inhibikase
Real-World Data Analysis of the Molecular Response Kinetics within the Two First Years of the RELMC-NOVA Study in Newly Diagnosed Spanish CML-CP Patients Treated with Tirosin Kinasa Inhibitors (TKIs) in First Line (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2559;
The responses obtained in the first months were higher and faster with the 2nd GTKIs but evened out after 12 months and remained similar at 2 years. Molecular response kinetics (HT or log red) can predict future response and should be assessed in patients with poor early responses.
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Tasigna (nilotinib) / Novartis, Inhibikase
Duration of =MR4 Is the Best Predictor for a Successful 1st Treatment-Free Remission (TRF1) Attempt in CML Patients Treated with Tyrosine Kinase Inhibitors (TKI); Long-Term Follow-up of a Large Cohort of Patients Including a Cohort Undergoing a 2nd Tfr (TFR2) Attempt (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2555;
Prior interferon treatment, longer period in =MR4 and a Sokal score <0.8 predicted a successful TFR. For those that fail TFR1, TFR2 appears safe, and with short follow-up, currently 9/13 (69%) patients remain off treatment.
- Bosulif (bosutinib) / Pfizer, Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Tasigna (nilotinib) / Novartis, Inhibikase
Effectiveness of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after Two or More Prior Tyrosine Kinase Inhibitors (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2551;
The number of patients in each registry was low, which may explain the variability of response and limits comparability across TKIs. However, a common pattern of treatment was observed across the 3 countries, with BOS and PON being used more frequently in patients treated with =3 prior TKIs; this could explain some of the differences in response rates.
- Venclexta (venetoclax) / Roche, AbbVie, Iclusig (ponatinib) / Takeda, Otsuka, Incyte
A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph+) Acute Myeloid Leukemia (AML) (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2547;
P2
In this poor-risk population, a marrow remission rate of 75% was achieved, although durations of remission were modest in the absence of consolidative SCT. This study continues to accrue pts.
- Viracept (nelfinavir) / ViiV Healthcare, Roche
The Anti-HIV Drug Nelfinavir Exhibits Synergistic Activity with Tyrosine Kinase Inhibitors and Circumvents TKI-Resistance Conferred By T315I-Mutated BCR-ABL (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2541;
Most importantly, low levels of NFV increased the Ponatinib efficiency in T315I-mutated BCR::ABL-expressing cells. These inhibitory effects implicate the activation of eEF2K with induction of interferon pathways.
- Nailike (olverembatinib) / Ascentage Pharma
The First Report of Third-Generation TKI Olverembatinib in Adult Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia with T315I Mutation and Relapsed Disease (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2254;
Methods In this exploratory study, adult Ph/BCR-ABL1+ ALL pts with T315I mutation or disease progression were treated with olverembatinib monotherapy (40 mg, every 2 days) or in combination with VP based low intensive chemotherapy (Vincristine/Prednisone) in our institution...Meanwhile, the olverembatinib-based therapy was well-tolerated, and the main adverse events of the third-generation TKIs, such as cytopenia, elevated transaminases, hypertension, and cardiovascular events, were less frequent than those reported relating to ponatinib...Conclusion This work suggests that Olverembatinib is a very promising 3rd-generation TKI. It is effective and safe in Chinese adult Ph/BCR-ABL1+ ALL with extremely poor prognosis, especially in T315I mutated or relapsed pts.
- Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2248;
This approach can also facilitate consolidative SCT in these pts. The therapy is well tolerated, but pts should be monitored for development of VOD of the liver, though the absolute risks remain low.
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Frontline Combination of Hyper-CVAD with Ponatinib for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia—6-Year Follow-up Results (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2247;
The overall CMR rate was 86% and the 5-year OS was 75%, which compares favorably with regimens using first- or second-generation TKIs in this population. The combination was safe; the use of lower doses of ponatinib maintained efficacy and mitigated the risk of ponatinib-related toxicity.
- Jakafi (ruxolitinib) / Novartis, Incyte, Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Blincyto (blinatumomab) / Astellas, Amgen
Outcomes of Patients with B-ALL with Concomitant BCR::ABL1 and CRLF2 Rearrangements (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2211;
Patients who harbor concomitant Ph+ and CRLF2-R represent a rare but high-risk subgroup of B-ALL. High rate of relapse was noted despite treatment with chemotherapy + TKI +/- ruxolitinib; several patients cleared the Ph+ clone, but CRLF2-R clone persisted suggesting novel interventions against CRLF2-R B-ALL are warranted.
- Venclexta (venetoclax) / Roche, AbbVie
PTPN11 Mutations Drive Tyrosine Kinase Inhibitor As Well As Venetoclax Resistance in Ph+ ALL Cells, but Are Sensitive to the Combination (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2188;
Somatic mutations in PTPN11 in Ph+ ALL lead directly to TKI as well as venetoclax resistance rendering these mono-therapies ineffective. Combination therapy with TKIs plus venetoclax could be a promising treatment option for Ph+ ALL patients carrying PTPN11 mutations.
- ELVN-001 / Enliven Therap
Elvn-001, a Next Generation ATP-Competitive ABL1 Tyrosine Kinase Inhibitor for the Treatment of Chronic Myeloid Leukemia (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2169;
Of the six small-molecule ABL1 tyrosine kinase inhibitors (TKIs) that have received FDA-approval for the treatment of BCR-ABL1-driven Chronic Myeloid Leukemia (CML), five (Imatinib, Nilotinib, Dasatinib, Ponatinib, Bosutinib) target the ATP-binding site in the kinase domain...Consistent with previously reported findings for ponatinib, while ELVN-001 showed little to no activity against cells expressing a subset of T315I-inclusive BCR-ABL1 compound mutants, the addition of Asciminib resulted in varying degrees of re-sensitizing these mutants to ELVN-001...These anti-tumor activities also compared favorably to currently approved therapies when evaluated head-to-head in these studies. Together, these findings support ELVN-001 as an extremely selective, novel ATP-competitive inhibitor of ABL1 kinase with superior pharmacokinetic and tolerability properties compared to currently approved TKIs and which retains activity against T315I and other key on-target resistance mutations, warranting its further investigation in patients with TKI-resistant/intolerant CML.
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry (ENMCC - 265-268) - Nov 4, 2022 - Abstract #ASH2022ASH_1758;
Imatinib was more used in de novo BC (p<.001), whilst ponatinib in pts with a previous CML (p=.016)...The outcome of lyBC is more favorable as compared to mBC, whilst the presence of CNS involvement and EMM had no significant impact on survival. Focused trials are warranted to identify the best treatment option for this still difficult disease.
- Bosulif (bosutinib) / Pfizer, Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Tasigna (nilotinib) / Novartis, Inhibikase
Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis (ENMCC - 265-268) - Nov 4, 2022 - Abstract #ASH2022ASH_1755;
Prior to third-line TKI therapy, 313 patients (88%) received imatinib; 156 patients (44%), dasatinib; 161 patients (45%), nilotinib; 35 patients (10%), bosutinib. Third-line ponatinib therapy is optimal selection for patients with CML-CP who failed prior 2 TKI therapies in the absence of T315I mutation.
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Blincyto (blinatumomab) / Astellas, Amgen
Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study (ENMCC - 265-268) - Nov 4, 2022 - Abstract #ASH2022ASH_1613;
This chemotherapy-free regimen results in high rates of CMR and NGS MRD negativity. Encouraging survival has been observed without the need for SCT.
- vodobatinib (SCO - 088) / Sun Pharma Advanced Research Company
Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy (ENMCC - 217-219) - Nov 4, 2022 - Abstract #ASH2022ASH_1381;
P1/2
Vodobatinib remains a potential option for these highly refractory pts. A phase 2 study (NCT02629692) of vodobatinib is currently ongoing in CML pts failing = 3 TKI including ponatinib.
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Nailike (olverembatinib) / Ascentage Pharma
Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) (ENMCC - 217-219) - Nov 4, 2022 - Abstract #ASH2022ASH_1379;
P1
Internal study identifier: HQP1351-CU101. Clinicaltrials.gov identifier: NCT04260022.
- Nailike (olverembatinib) / Ascentage Pharma
A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China (ENMCC - 217-219) - Nov 4, 2022 - Abstract #ASH2022ASH_1378;
Olverembatinib also demonstrated meaningful potency in patients with CML with compound mutations. Internal study identifier: HQP1351-SJ0002.
- ||||| Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Blincyto (blinatumomab) / Astellas, Amgen
Clinical: Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia #ASH22 #ALL #leusm https://t.co/iO2eKX3H6l (Twitter) - Nov 3, 2022
- ||||| Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Blincyto (blinatumomab) / Astellas, Amgen
Clinical: Ponatinib and Blinatumomab for Patients with R/R Ph + #ALL or CML in Lymphoid Blast Phase https://t.co/R0W3D8PRd6 #leusm (Twitter) - Nov 3, 2022
- |||| Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Clinical: Frontline Combination of Hyper-CVAD with Ponatinib for Patients with Philadelphia Chromosome-Positive #ALL —6-Year Follow-up Results https://t.co/84TbzxKyUc (Twitter) - Nov 3, 2022
- |||| Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Extensive Leukemia Cutis...Seen for the 1 st time...flooding with blasts... (CML BC on Ponatinib) (Twitter) - Nov 2, 2022
- || Review, Journal: Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. (Pubmed Central) - Oct 31, 2022
Regimens including venetoclax in myeloid BP or inotuzumab ozogamicin or blinatumomab in lymphoid BP might lead to deeper and longer responses, facilitating potentially curative allo-SCT for patients with CML-BP once CP is achieved. Newer agents and novel combination therapies are further expanding the therapeutic arsenal in advanced phase CML.
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte
A RETROSPECTIVE ANALYSIS FROM THE MONITORING REGISTERS OF THE ITALIAN MEDICINAL AGENCY (AIFA) FOR PONATINIB (RAFFAELLO ROOM) - Oct 29, 2022 - Abstract #SIE2022SIE_292;
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte
USE OF PONATINIB IN PROPHYLAXIS OR PRE-EMPTIVE TO PREVENT CYTOLOGICAL RELAPSE AFTER ALLOGENIC TRANSPLANTATION IN PH-POSITIVE LAL (LEONARDO ROOM) - Oct 29, 2022 - Abstract #SIE2022SIE_276;
- | Biomarker, Journal: Early Reduction of Glucose Consumption Is a Biomarker of Kinase Inhibitor Efficacy Which Can Be Reversed with GLUT1 Overexpression in Lung Cancer Cells. (Pubmed Central) - Oct 27, 2022
Our results demonstrate that the early inhibition of lung cancer glucose consumption in response to a kinase inhibitor is a strong biomarker of and is often required for the subsequent inhibition of cell growth. Early inhibition of glucose consumption may provide complementary information to other biomarkers in determining whether a drug will effectively limit tumor growth.
- || Iclusig (ponatinib) / Takeda, Otsuka, Incyte
CML blast Crisis is no longer a " Blast " . It definitely is a Crisis but a short lived...reversed by stronger and more powerful guns like Ponatinib...🙏🙏 (Twitter) - Oct 26, 2022
- | Iclusig (ponatinib) / Takeda, Otsuka
Enrollment change, Trial termination: Retrospective Evaluation of CML Patients in the National Compassionate Program (clinicaltrials.gov) - Oct 26, 2022
P=N/A, N=38, Terminated, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Early inhibition of glucose consumption may provide complementary information to other biomarkers in determining whether a drug will effectively limit tumor growth. N=80 --> 38 | Recruiting --> Terminated; lack of interest
- ||| Review, Journal, Adverse events: Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia. (Pubmed Central) - Oct 25, 2022
In addition to imatinib, second- and third-generation tyrosine kinase inhibitors (TKIs) and a novel allosteric inhibitor, asciminib, are now available...Given the high efficacy of TKI therapy, dose modifications of TKI therapy reduce the risk of toxicities and improves quality of life during therapy. In this review article, we summarize the characteristics and adverse event profile of each TKI and dose modifications in patients with CML-CP and discuss future perspectives in the treatment of CML-CP.
- | Bosulif (bosutinib) / Pfizer, Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Tasigna (nilotinib) / Novartis, Inhibikase
Retrospective data, Journal: Allogeneic hematopoietic cell transplantation in patients with CML chronic phase in the era of third generation tyrosine kinase inhibitors: a retrospective study by the Chronic Malignancies Working Party of the EBMT. (Pubmed Central) - Oct 22, 2022
No difference in OS, PFS, RI or NRM was evident related to the number of TKI prior to allo-HCT or to the type of TKI (p=ns). Significant factors influencing OS and PFS were >CP1 vs CP1 and Karnofsky performance (KPS) score >?80 vs ?80, highlighting CP1 patients undergoing allo-HCT have improved survival compared to >CP1 and the importance of careful allo-HCT candidate selection.
- || Scemblix (asciminib) / Novartis
Review, Journal: Asciminib for chronic myeloid leukaemia: Next questions. (Pubmed Central) - Oct 22, 2022
In this review, we discuss the available data on asciminib while exploring a number of clinical trials in progress. Finally, we provide our opinion based on the current data about where asciminib is most likely to be the optimal choice, which will hopefully assist clinicians with therapy selection.
- | Iclusig (ponatinib) / Takeda, Otsuka, Incyte, chlorogenic acid / Jiuzhang Biotech
Journal: Discovery of anti-stroke active substances in Guhong injection based on multi-phenotypic screening of zebrafish. (Pubmed Central) - Oct 22, 2022
Molecular docking suggested strong affinities between baicalein and F7, and between active substances (baicalein, chlorogenic acid, gallic acid, and rutin) and NF-κB p65. In summary, our findings established a novel drug discovery method based on multi-phenotypic screening of zebrafish, provided endogenous evidences of GHI in preventing thrombus formation and promoting behavioral recovery after cerebral ischemia, and identified baicalein, rutin, chlorogenic acid, and gallic acid as active compounds in the management of ischemic stroke.